SEATTLE, Jan. 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX: CTIC) announced today that it priced an offering of 800,000 shares of CTI new common shares. This share issue will equate to approximately 1.2% percent of CTI's market capitalization. The offering is expected to close on Wednesday, January 16, and to raise approximately $1,270,000 (euros 856.000). The shares will be sold to Societe Generale, pursuant to the Step-Up Equity Financing Agreement entered into by CTI and Societe Generale, dated June 21, 2006 as amended. CTI intends to use the net proceeds for general corporate purposes, including the preparation and filing of new drug applications and preclinical and clinical trials.
A shelf registration statement relating to the shares issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. A listing prospectus relating to this offering was also published in Italy on January 14, 2008, and the shares sold in the offering are registered in Italy pursuant to that listing prospectus. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock. No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.
This press release includes forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results. Specifically, there is a
risk that the transaction referred to in this press release may be delayed
or may not ultimately close if certain conditions set forth in the Step-Up
Equity Financing Agreement are not satisfied. You should also review the
risk factors listed or described from time to time in the Company's filings
with the Securities and Exchange Commission including, without limitation,
the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as
may be required by Italian law, CTI does not intend to update or alter its
forward-looking statements whether as a result of new information, future
events, or otherwise.
Cell Therapeutics, Inc.
Dan Eramian or Susan Callahan
T: 206.272.4343 or 206.272.4472
Cell Therapeutics, Inc.
|SOURCE Cell Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved